Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.39 |
| ▸ | ITGB7 | P26010 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3978720 | 0.94 | ITGA4 (0.44) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5926509 | 0.88 | ITGA4 (0.44) | ITGB1ITGA4ITGB7 | |
| SCHEMBL3998771 | 0.85 | ITGA4 (0.42) | ITGB1ITGA4ITGB7 | |
| SCHEMBL3977295 | 0.85 | TACR3 (0.40) | TACR3 | |
| SCHEMBL4255107 | 0.85 | PTGER4 (0.41) | — | |
| SCHEMBL3973838 | 0.84 | ABCG2 (0.45) | PYGLTACR3CDK2PSMB5ITGB1 | |
| SCHEMBL5926298 | 0.83 | ITGA4 (0.47) | ITGB1ITGA4ITGB7 | |
| SCHEMBL4824030 | 0.83 | PYGL (0.48) | PYGLTACR3CDK2PSMB5ITGB1 | |
| SCHEMBL4824034 | 0.83 | PYGL (0.48) | PYGLTACR3CDK2PSMB5ITGB1 | |
| SCHEMBL3971232 | 0.82 | PYGL (0.47) | PYGLTACR3CDK2PSMB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | VTVX HOLDINGS I LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2005014532-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | EPOR, HBG2, CYP2F1 | PYGL 202/4885TACR3 3391/4885CDK2 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.